What is the recommended dosing of aripiprazole (Abilify) for a 14‑year‑old?

Aripiprazole (Abilify) Dosing for 14-Year-Olds

For a 14-year-old, the recommended aripiprazole dose depends on the indication: for schizophrenia or bipolar I disorder, start at 2 mg/day, titrate to 5 mg after 2 days, then to the target dose of 10 mg/day after 2 additional days. 1

Indication-Specific Dosing

Schizophrenia (Ages 13-17)

• Starting dose: 2 mg/day 1
• Titration schedule:
  • Increase to 5 mg after 2 days
  • Increase to target dose of 10 mg/day after 2 additional days 1
• Target dose: 10 mg/day 1
• Maximum studied dose: 30 mg/day, though this was not shown to be more efficacious than 10 mg/day 1
• Subsequent dose increases: Should be administered in 5 mg increments if needed 1
• Can be administered without regard to meals 1

Bipolar I Disorder - Manic or Mixed Episodes (Ages 10-17)

• Starting dose: 2 mg/day 1
• Titration schedule:
  • Increase to 5 mg/day after 2 days
  • Increase to target dose of 10 mg/day after 2 additional days 1
• Target dose: 10 mg/day as monotherapy or adjunctive to lithium/valproate 1
• Subsequent increases: Administer in 5 mg/day increments if needed 1
• Can be given without regard to meals 1

Irritability Associated with Autistic Disorder (Ages 6-17)

• Starting dose: 2 mg/day 1
• Titration: Increase to 5 mg/day, with subsequent increases to 10 or 15 mg/day if needed 1
• Dosage range: 5 to 15 mg/day 1
• Dose adjustments: Up to 5 mg/day should occur gradually, at intervals of no less than one week 1

Tourette's Disorder (Ages 6-18)

For patients weighing ≥50 kg (typical for most 14-year-olds):

• Starting dose: 2 mg/day for 2 days 1
• Titration: Increase to 5 mg/day for 5 days, then to target dose of 10 mg/day on Day 8 1
• Maximum dose: Can be increased up to 20 mg/day for patients who do not achieve optimal control of tics 1
• Dose adjustments: Should occur gradually in increments of 5 mg/day at intervals of no less than one week 1

Clinical Evidence Supporting Dosing

Efficacy Data

• In adolescents (13-17 years) with schizophrenia, the 10 mg/day dose was as effective as 30 mg/day, making higher doses unnecessary 1
• In pediatric bipolar I disorder studies, both 10 mg/day and 30 mg/day demonstrated efficacy, but the 10 mg/day dose had better tolerability 2
• Completion rates in long-term studies were highest with the 10 mg/day dose (45.3%) compared to 30 mg/day (31.0%) 2

Tolerability Considerations

• Tolerability is more favorable in adolescents aged ≥13 years compared to younger children (10-12 years) 3
• The 10 mg/day dose demonstrates better tolerability than 30 mg/day in pediatric populations 3, 2
• Common adverse events include sedation, weight gain, and extrapyramidal symptoms, though EPS incidence at 10 mg/day was not significantly different from placebo over 12 weeks 3
• Mean weight gain at 8 weeks with 5-15 mg/day dosing ranged from +1.3 to +1.5 kg 4

Critical Monitoring Requirements

Metabolic Monitoring

• Baseline: BMI, waist circumference, blood pressure, fasting glucose, and fasting lipid panel 5
• Follow-up monitoring: As specified in guidelines for ongoing metabolic surveillance 5

Suicidality Monitoring

• Close monitoring required: Especially in the first months of treatment and following dosage adjustments 1
• FDA warning: Antidepressants (and by extension, adjunctive antipsychotics) increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults 1
• Families and caregivers need education about the need for close observation and communication with the prescriber 1

Dosage Adjustments for Drug Interactions

When CYP450 interactions are present, dose adjustments are necessary 1:

• Strong CYP3A4 inhibitors or CYP2D6 inhibitors: Reduce aripiprazole dose to one-half (50%) of usual dose
• Strong CYP3A4 inducers: May require dose increases; when withdrawn, reduce dose over 1-2 weeks
• Combination of strong/moderate inhibitors: May require reduction to one-quarter (25%) of usual dose

Important Clinical Pitfalls

• Avoid premature dose escalation: Dosage increases should generally not be made before 2 weeks in adults, and should follow the specified titration schedule in adolescents 1
• Age and weight matter: Caution is advised for smaller children (<34 kg) and those <8.6 years old, though most 14-year-olds will not fall into these categories 6
• Sedative medication interactions: Coadministration with sedative medications (particularly guanfacine or clonidine) increases the risk of adverse events such as increased lability and aggression 6
• Maintenance duration: Continue treatment for at least 12-24 months after symptom stabilization, as withdrawal dramatically increases relapse risk 5